Epidemiologia dos acidentes por animais peçonhentos e a distribuição de soros: estado de arte e a situação mundial
Epidemiology of accidents by venomous animals and distribution of antivenon: state of art and world status
Epidemiología de accidentes por animales venenosos y distribución de suero: estado de arte y situación mundial
DOI:
https://doi.org/10.15446/rsap.v20n4.70432Keywords:
Animais peçonhentos, soro, desenvolvimento tecnológico, políticas públicas de saúde (pt)Poisonous animals, serum, technological development, public health policy (en)
Animales venenosos, suero, desarrollo tecnológico, politicas publicas de salud (es)
Downloads
Acidentes por animais peçonhentos são discutidos sob perspectiva histórica de ações de estado. Considerados doenças negligenciadas eles causam prejuízos sociais e econômicos, em pessoas em idade produtiva de regiões rurais em países pobres. Poucos países dispõem de políticas públicas de saúde para profilaxia e tratamento adequados e as maiores perdas ocorrem na África e Ásia. Os 46 produtores mundiais de soros não suprem as necessidades globais e acesso ao tratamento é difícil, mesmo em países com produção própria. Sistemas de Notificação produzem levantamentos imprecisos sobre necessidades de soro e apesar da notificação compulsória. O Brasil carece de bancos de dados robustos de amplo acesso, que permita uma distribuição do soro em tempo seguro para o atendimento de qualidade. Muito se avançou em testes diagnóstico, porém sua aplicação em áreas pobres é inviabilizada pelos custos. Melhorias na qualidade de produção dos soros, via boas práticas laboratoriais e fabris, minimizam resultados insatisfatórios de tratamentos com produtos de origem e ação duvidosa. Desenvolvimento de soros empregando Biotecnologia e Ensaios Clínicos bem desenhados, são chave para tratamento de envenenamentos por agentes aparentados em diferentes regiões (soros continentais ou universais). Parcerias internacionais são fundamentais, além de estoques reguladores, semelhantes aos adotados em vacinas, para suprir a demanda mundial. A qualificação dos soros antivenenos certamente minimizará equívocos de uso. Apoio governamental à pesquisa é alavanca propulsora e a ferramenta mais eficiente de preservação da vida, evitando sobrecargas social e previdenciária principalmente em países em desenvolvimento.
Accidents by venomous animals are discussed under the historical perspective of state actions. Considered as neglected diseases, they cause social and economic losses in the working age population from rural areas of poor countries, as few of them have public health policies for adequate prophylaxis and treatment; in fact, the largest life losses occur in Africa and Asia. The 46 world producers of antivenin do not meet the global needs, making access to treatment difficult, even in countries with own production. Notification systems lead to inaccurate surveillance surveys and antivenin needs. Despite mandatory notification, Brazil lacks robust databases with full open access in order to allow the timely distribution of antivenin for quality care of these patients. Progress has been made in diagnostic testing, but its application in poor areas is not feasible due to high costs. Improvements in quality antivenin production through good laboratory practices and manufacturing minimize unsatisfactory results of treatments carried out with products of dubious origin. Antivenin development using biotechnology and well-designed clinical trials are key for the treatment of envenoming by agents phylogenetically related from different regions (continental or universal antivenins). International partnerships are fundamental, besides regulatory stocks, similarly to those adopted for vaccines, to supply world demand. The qualification of antivenin will certainly minimize treatment mistakes. Government support to research is a driving force and the most efficient tool for preserving life and avoiding social security surcharges, particularly in developing countries.
Accidentes por animales venenosos se discuten desde una perspectiva histórica de acciones de estado. Consideradas enfermedades olvidadas, causan perjuicios sociales y económicos, en personas en edad productiva de regiones rurales en países pobres. Pocos países disponen de políticas públicas de salud para profilaxis y tratamiento adecuados y las mayores pérdidas ocurren en África y Asia. Los 46 productores mundiales de sueros no suplen las necesidades globales y el acceso al tratamiento es difícil, incluso en países con producción propia. Los sistemas de notificación generan levantamientos imprecisos sobre las necesidades de suero ya pesar de la notificación obligatoria, Brasil carece de bases de datos robustas de amplio acceso, permitiendo la llegada del suero en tiempo seguro para la atención de calidad. Se ha avanzado mucho en pruebas diagnósticas, pero su aplicación en áreas pobres es inviabilizada por los costos. Mejoras en la calidad de producción de los sueros, a través de buenas prácticas de laboratorio y fabril, minimizan resultados insatisfactorios de tratamientos con productos de origen y acción dudosa. El desarrollo de sueros empleando Biotecnología y Ensayos Clínicos bien diseñados, son clave para el tratamiento de envenenamientos por agentes emparentados en diferentes regiones (sueros continentales o universales). Las alianzas internacionales son fundamentales, además de stocks reguladores, similares a los adoptados en vacunas, para suplir la demanda mundial. La pre cualificación de los sueros antivenenos ciertamente minimizará equívocos de uso. El apoyo gubernamental a la investigación es la palanca propulsora y la herramienta más eficiente de preservación de la vida, evitando sobrecargas social y previsional principalmente en países en desarrollo.
References
Hunt P. Neglected diseases: A human rights analysis. Special topics in social, economic and behavioural research report series 2007; no. 6 WHO.
Gutiérrez JM, Theakston RDG, Warrell DA. Confronting the neglected problem of snake bite envenoming: the need for a global partnership. PLoS Med 2006; 3:e150.
Kasturiratne A, Pathmeswaran A, Wickremasinghe AR, Jayamanne SF, Dawson A, Isbister GK, Silva HJ, Lalloo DG. The socio-economic burden of snakebite in Sri Lanka. PLoS Negl Trop Dis. 2017; 11(7):e0005647.
Harrison RA, Gutiérrez JM. Priority Actions and Progress to Substantially and Sustainably Reduce the Mortality, Morbidity and Socioeconomic Burden of Tropical Snakebite. Toxins 2016; 8, 351:1-14.
Chippaux JP. Snakebite envenomation turns again into a neglected tropical disease! Journal of Venomous Animals and Toxins including Tropical Diseases. 2017; 23:38.
Scheske L, Ruitenberg J, Bissumbhar B. Needs and availability of snake antivenoms: relevance and application of international guidelines. Int J Health Policy Manag. 2015; 4(7): 447–457.
Alirol E, Sharma SK, Bawaskar HS, Kuch U, Chappuis F. Snake Bite in South Asia: A Review. PLOsNTDs. 2010; 4(1):1-9.
Chippaux JP, Goyffon M. Producers of antivenomous sera. Toxicon. 1993; 21(6):739-752.
Gutiérrez JM. Improving antivenom availability and accessibility: Science, technology, and beyond. Toxicon. 2012; 60(4):676-687.
Boyer LV. On 1000-fold pharmaceutical price markups, and why drugs cost more in the US than in Mexico. The American Journal of Medicine. 2015; 128(12):1265-7.
Warrell D. Unscrupulous marketing of snake bite antivenoms in Africa and Papua New Guinea: choosing the right product ‘What’s in a name? Trans Royal Soc Trop Med Hyg. 2008; 102:397-9.
Chippaux JP. Estimating the global burden of snakebite can help to improve management. PLoS Med. 2008; 5:e221.
Hamza M, Idris MA, Maiyaki MB, Lamorde M, Chippaux JP, Warrell DA, Kuznik A, Habib AG. Cost-Effectiveness of Antivenoms for Snakebite Envenoming in 16 Countries in West Africa. PLOS Neglected. 2016; 10(3): e0004568.
Guidolin FR, Caricati CP, Marcelino JR, da Silva WD. Development of Equine IgG Antivenoms against Major Snake Groups in Mozambique. PLoS Negl Trop Dis. 2016; 10(1):e0004325.
Brown NI. Consequences of Neglect: Analysis of the Sub-Saharan African Snake Antivenom Market and the Global Context. PLoS Negl Trop Dis. 2012; 6(6): e1670.
Portal Saúde. NOTA INFORMATIVA: Informações da Coordenação-Geral de Doenças Transmissíveis (CGDT) referentes à nova abordagem ao tratamento em casos de acidentes por serpentes do grupo Bothrops (“jararacas”) e por escorpiões, em situação de escassez de antivenenos. 2017. http://portalsaude.saude.gov.br (acesso 15/05/2017).
Carvalho MS. Informação: da produção à utilização. In: Rozenfeld, S. (Org.). Fundamentos da vigilância sanitária. Rio de Janeiro: Editora. Fiocruz; 2000. p.235- 256.
Cardoso JLC, França FOS, Wen FH, Málaque CMS, Haddad Jr V. Animais Peçonhentos No Brasil: Biologia, Clínica e Terapêutica dos Acidentes. 2ª. Ed, Ed. Sarvier 2009.
Fiszon JT, Bochner R. Subnotificação de acidentes por animais peçonhentos registrados pelo SINAN no Estado do Rio de Janeiro no período de 2001 a 2005 Underreporting of accidents with venomous animals registered by SINAN in the State of Rio de Janeiro from 2001 to 2005. Rev Bras Epidemiol. 2008; 11(1):114-27.
Machado C, Bochner R. A informação dos acidentes crotálicos no Estado
do Rio de janeiro, 2001 a 2010. Gazeta Med Bahia. 2012; 82 (1):78-84.
Gutiérrez JM, Lomonte B, León G, Alape-Girón A, Flores-Díaz M, Sanz L, Angulo Y, Calvete JJ. Snake venomics and antivenomics: Proteomic tools in the design and control of antivenoms for the treatment of snakebite envenoming. J Proteomics 2009; 165-182.
Isbister GK, Brown SGA, Page GB, MacCoubrie DL, Greene SL, Buckley NA. Snakebite in Australia: a practical approach to diagnosis and treatment. MJA. 2013; 199:763-768.
Theakston RDG, Gavin D, Laing GD. Diagnosis of Snakebite and the Importance of Immunological Tests in Venom research. Toxins. 2014; 6(5): 1667-95.
Villalta M, Sánchez A, Herrera M, Vargas M, Segura Á, Cerdas M, et al. Development of a new polyspecific antivenom for snakebite envenoming in Sri Lanka: Analysis of its preclinical efficacy as compared to a currently available antivenom. Toxicon 2016; 122:152-159.
Jorge RJB, Monteiro HSA, Gonçalves-Machado L, Guarnieri MC, Ximenes RM, Borges-Nojosa DM, Luna KPO, Zingali RB, Corrêa-Netto C, Gutiérrez JM, Sanz L, Calvete JJ, Pla D. Venomics and antivenomics of Bothrops erythromelas from five geographic populations within the Caatinga ecoregion of northeastern Brazil. J Proteomics. 2015; 114: 93-111.
Gutiérrez JM, Sanz L, Escolano J, Fernandez J, Lomonte B, Angulo Y, Rucavado A, Warrell DA, Calvete JJ. Snake Venomics of the Lesser Antillean Pit Vipers Bothrops caribbaeus and Bothrops lanceolatus: Correlation with Toxicological Activities and Immunoreactivity of a Heterologous Antivenom. J Proteome Res. 2008; 7:4396–4408.
Thomas L, Tyburn B, Ketterlé J, Blao T, Mehdaoui H, Moravie V, Rouvel C, Plumelle Y, Bucher B, Canonge D, Marie-Nelly CA, Lang J, Research Group on Snake Bite in Martinique. Prognostic significance of clinical grading of patients envenomed by snake Bothrops lanceolatus in Martinique. Trans R Soc Trop Med Hyg. 1998; 92:542-545.
Malbranque S, Piercecchi-Marti MD, Thomas L, Barbey C, CourcierD, Bucher B, Ridarch A, Smadja D, Warrell DA. Case Report fatal diffuse thrombotic microangiopathy after a bite by the “Fer-de-Lance” pit viper (Bothrops lanceolatus) of Martinique. Am J Trop Med Hyg. 2008; 78(6):856-861.
Segura A, Herrera M, Vargas M, Villalta M, Uscanga-Reynell A, León G, Gutiérrez JM. Preclinical efficacy against toxic activities of medically relevant Bothrops sp. (Serpentes: Viperidae) snake venoms by a polyspecific antivenom produced in Mexico. Rev Biol Trop. 2017; 65(1):345-350.
Bush SP, Ruha A-M, Seifert SA, Morgan DL, Lewis BJ, Arnold TC,Clark RF, Meggs WJ, Toschlog EA, Borron SW, Figge GR, Sollee DR, Shirazi FM, Wolk R, Chazal I de, Quan D, García-Ubbelohde W, Alagón A, Gerkin RD, Boyer LV. Comparison of F(ab’)2 versus Fab antivenom for pit viper envenomation: A prospective, blinded, multicenter, randomized clinical trial. Clinical Toxicology. 2015; 53(1):37-45, 31. Cardoso JL, Fan HW, França FO, Jorge MT, Leite RP, Nishioka SA, Avila A, Sano-Martins IS, Tomy SC, Santoro ML. Randomized comparative trial of three antivenoms in the treatment of envenoming by lance-headed vipers (Bothrops jararaca) in São Paulo, Brazil. Quart J Med. 1993; 86(5):315-325.
Pardal PPDO, Souza SM, Monteiro MRDCDC, Fan HW, Cardoso JLC, França FOS, Tomy SC, Sano-Martins IS, de Sousa-e-Silva MCC, Colombini M, Kodera NF. Clinical trial of two antivenoms for the treatment of Bothrops and Lachesis bites in the north eastern Amazon region of Brazil. Trans R Soc Trop Med Hyg. 2004; 98(1):28-42.
Ediriweera DS, Kasturiratne A, Pathmeswaran A, Gunawardena NK, Wijayawickrama BA, Jayamanne SF, Isbister GK, Dawson A, Giorgi E, Diggle PJ, Lalloo DG, de Silva HJ. Mapping the risk of snakebite in Sri Lanka-A national survey with geospatial analysis. PLoS Negl Trop Dis. 2016; 10, e0004813.
Bawaskar HS, Bawaskar PH, Bawaskar PH. Snake bite in India: a neglected disease of poverty. The Lancet. 2017; 390:1947-194.
Gutiérrez J-M, Burnouf T, Harrison RA, Calvete JJ, Kuch U, Warrell DA. A ulticomponent strategy to improve the availability of antivenom for treating snakebite envenoming. Bull World Health Organ. 2014; 92:526-32.
Chippaux JP. Prise en charge des piqûres de scorpion en Afrique et au Moyen-Orient Management of scorpion stings in Africa and the Mediterranean region. Médecine et Santé Tropicales. 2016; 26:130-133.
Debono J, Dobson J, Casewell NR, Romilio A, Li B, Kurniawan N, Mardon K, Weisbecker V, Nouwens A, Kwok HF, Fry BG. Coagulating Colubrids: Evolutionary, Pathophysiological and Biodiscovery Implications of Venom Variations between Boomslang (Dispholidus typus) and Twig Snake (Thelotornis mossambicanus). Toxins 2017; 9: 171.
Harrison RA, Oluoch GO, Ainsworth S, Alsolaiss J, Bolton F, Arias A-S, Gutierrez J.-M, Rowley P, Ozwara H, Casewell NR. Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa. PLoS Negl Trop Dis 2017; 11(10): e0005969.
Angarita-Gerlein D, Bravo-Vega CA, Cruz C, Forero-Muñoz NR, Navas-Zuloaga MG, Umaña-Caro JD. Snakebite Dynamics in Colombia: Effects of Precipitation Seasonality on Incidence. IBIO4299 International Research Experience For Students IRES 2017, disponível em https://goo.gl/LoR9GR.
Mendonça-da-Silva I., Magela Tavares, A., Sachett, J., Sardinha, J. F., Zaparolli, L. et al. Safety and efficacy of a freeze-dried trivalent antivenom for snakebites in the Brazilian Amazon: An open randomized controlled phase IIb clinical trial. PLoS Negl Trop Dis11(11):e0006068. 2017.
How to Cite
APA
ACM
ACS
ABNT
Chicago
Harvard
IEEE
MLA
Turabian
Vancouver
Download Citation
License
Copyright (c) 2018 Revista de Salud Pública
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This journal provides immediate free access to its content under the principle that making research available to the public free of charge supports a greater exchange of global knowledge.
All contents of this journal, except where identified, are published under a Creative Commons Attribution 4.0 License